SSRIs Do Not Appear to Increase Cardiovascular Risk

Share this content:
SSRIs Do Not Appear to Increase Cardiovascular Risk
SSRIs Do Not Appear to Increase Cardiovascular Risk

WEDNESDAY, March 23, 2016 (HealthDay News) -- Selective serotonin reuptake inhibitors (SSRIs) don't appear to raise cardiovascular risk among young and middle-age patients, according to research published online March 22 in The BMJ.

Carol Coupland, Ph.D., a professor of medical statistics in primary care at the University of Nottingham in the United Kingdom, and colleagues analyzed data collected by the U.K. QResearch database, which covers more than 12 million British patients treated at 600 general practice facilities. Of these patients, 238,963 were between 20 and 64 years old and diagnosed with depression between 2000 and 2011; 71.3 percent were taking SSRIs. Their heart health was tracked until 2012.

During roughly five years of follow-up, 772 patients experienced a myocardial infarction, 1,106 had a stroke or transient ischemic attack, and 1,452 were diagnosed with an arrhythmia. When the study team looked at different types of antidepressants, as well as dosage and duration, they found no significant association between SSRIs and an increased risk for myocardial infarction, stroke, or arrhythmia. Overall, myocardial infarction risk was lower for those taking SSRIs when compared with those who took no antidepressants of any kind.

Fluoxetine seemed particularly protective, in terms of reducing risk for myocardial infarction and arrhythmia, the researchers said. And citalopram was not linked to any increase in heartbeat irregularity risk, even at relatively high doses, despite a related U.S. Food and Drug Administration safety warning issued in 2011. Nevertheless, "with this type of observational study it isn't possible to make firm conclusions about cause and effect," Coupland told HealthDay.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

FDA OKs Doptelet for Liver Dz Patients Undergoing ...

Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure

Slower Decline in Lung Function With Anthocyanin Intake

Slower Decline in Lung Function With Anthocyanin Intake

Slower annual rates of decline in FEV1 and FVC for those in highest quartile of anthocyanin intake

Bioengineering Feasible for Airway Reconstruction

Bioengineering Feasible for Airway Reconstruction

Bioengineered tracheal and bronchial reconstruction reported using stented aortic matrices

is free, fast, and customized just for you!

Already a member?

Sign In Now »